Anti-ARIH2/TRIAD1 antibody [EPR7671] - BSA and Azide free

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

ARIH2 also known as TRIAD1 is a RING-between-RING (RBR) E3 ubiquitin-protein ligase. It weights approximately 65 kDa. This protein facilitates the transfer of ubiquitin from E2 enzymes to substrates marking them for proteasomal degradation. ARIH2 is located mostly in the cytoplasm and nucleoplasm with high expression in immune cells such as macrophages and dendritic cells. It regulates ubiquitination which is important for controlling protein levels in the cell affecting cellular signal pathways and homeostasis.

Biological function summary

ARIH2 acts as an essential modulator of immune responses. By associating with the LUBAC complex (linear ubiquitin chain assembly complex) this protein contributes to the linear ubiquitination of specific substrates modulating immune signaling. Its activity affects the NF-κB signaling pathway a vital pathway in inflammation and immunity. ARIH2 influences anti-inflammatory responses and may balance immune homeostasis making it a critical player in immune system regulation.

Pathways

ARIH2 plays a significant role in the ubiquitylation pathway and the NF-κB signaling pathway. The protein cooperates with other members of the pathway like HOIP and SHARPIN to mediate immune responses through linear ubiquitin chains. This regulation influences the activation of NF-κB leading to changes in gene expression related to immune and inflammatory responses. ARIH2 is also involved in the regulation of the Wnt signaling pathway where it interacts with various signaling proteins to modulate developmental processes and cellular growth.

Associated diseases and disorders

ARIH2 has implications in autoimmune diseases and cancer. Its regulation of immune responses connects it to autoimmune conditions where the body's immune system attacks its own cells. By influencing NF-κB signaling through proteins like LUBAC ARIH2 affects inflammation contributing to the pathogenesis of autoimmune diseases. In cancer ARIH2's role in protein degradation pathways can alter cell growth and survival connecting it to tumor development and progression. Its interaction with proteins such as HOIP in these pathways suggests its potential as a therapeutic target for both autoimmune disorders and cancer.